Loading…
AgomAb Therapeutics NV is projected to decline to $11.10 by 2027, a -5% move from its current price of $11.67. AGMB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.24 | $11.67 | $12.11 | -0.02% |
| May 30 | $11.07 | $11.67 | $12.29 | -0.04% |
| May 31 | $10.94 | $11.66 | $12.43 | -0.06% |
| Jun 1 | $10.83 | $11.66 | $12.56 | -0.08% |
| Jun 2 | $10.73 | $11.66 | $12.66 | -0.10% |
| Jun 3 | $10.65 | $11.66 | $12.76 | -0.12% |
| Jun 4 | $10.57 | $11.65 | $12.85 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.57 | $11.65 | $12.85 | -0.13% |
| Week 2 | $10.13 | $11.64 | $13.37 | -0.27% |
| Week 3 | $9.81 | $11.62 | $13.77 | -0.40% |
| Week 4 | $9.54 | $11.61 | $14.12 | -0.54% |
| Week 5 | $9.31 | $11.59 | $14.43 | -0.67% |
| Week 6 | $9.11 | $11.58 | $14.71 | -0.81% |
| Week 7 | $8.92 | $11.56 | $14.98 | -0.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company that develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. Its pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models.
The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
AGMB is trading at $11.50 and has a market cap of $566.35M. It is ranked 2946. The current price reflects a position within a smaller market-cap segment, and the near-term outlook is framed by a neutral momentum pattern.
The 2026 forecast shows an average of $11.50 with a range from $9.85 to $15.71, highlighting a cautious near-term path. Looking further ahead, the forecast depicts a bullish shift with rising averages and ROIs through 2031 and beyond, culminating in substantial upside by 2050.
A major floor 18.0% below — a decisive break under it would weaken the trend.
The nearest floor, 9.9% below — buyers have tended to step in here.
The nearest ceiling, 7.1% above — a clean break opens room to run.
A major ceiling 38.9% above — clearing it would confirm fresh momentum.
Key AGMB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AGMB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.17 | Buy | $11.26 | Buy |
| MA 10 | $10.97 | Buy | $11.20 | Buy |
| MA 20 | $11.36 | Buy | $11.23 | Buy |
| MA 50 | $11.30 | Buy | $11.71 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.67 | Neutral |
| Stoch RSI (14) | 87.84 | Sell |
| CCI (20) | 37.15 | Neutral |
| Williams %R (14) | -30.54 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -3.79 | Sell |
| Bollinger %B (20,2) | 0.62 | Neutral |
| Stochastic %K (14) | 69.46 | Neutral |
| TRIX (15) | -0.11 | Sell |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 63.90 | Neutral |
| Momentum (10) | -0.41 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 11.48 | Buy |
| ADX (14) | 10.68 | Neutral |
| ATR (14) | 0.40 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 50 and the stock sits near the 50-day simple moving average of $11.41. The chart shows a defined near-term support at $10.42 and a resistance at $12.50. The 30-day price range spans from $9.04 to $14.63, reflecting recent volatility. Annualized volatility is 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.85 | $11.67 | $15.97 | 0% | Neutral | |
| $7.92 | $11.10 | $16.84 | -5% | Neutral | |
| $7.15 | $10.66 | $17.22 | -9% | Neutral | |
| $7.40 | $11.64 | $19.74 | 0% | Neutral | |
| $7.25 | $11.99 | $21.17 | +3% | Neutral | |
| $8.72 | $15.10 | $27.61 | +29% | Bullish | |
| $9.44 | $17.09 | $32.22 | +46% | Bullish | |
| $8.13 | $15.36 | $29.78 | +32% | Bullish | |
| $8.11 | $15.98 | $31.78 | +37% | Bullish | |
| $8.04 | $16.52 | $33.62 | +42% | Bullish | |
| $11.10 | $24.68 | $55.27 | +111% | Bullish | |
| $16.74 | $37.19 | $85.55 | +219% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $9.85 | $11.67 | $13.90 | +0.00% |
| June 2026 | $9.62 | $11.56 | $14.40 | -0.96% |
| July 2026 | $9.38 | $11.47 | $14.67 | -0.79% |
| August 2026 | $9.53 | $11.82 | $15.42 | +3.05% |
| September 2026 | $9.35 | $11.73 | $15.55 | -0.76% |
| October 2026 | $8.84 | $11.21 | $15.08 | -4.42% |
| November 2026 | $8.79 | $11.25 | $15.33 | +0.39% |
| December 2026 | $8.97 | $11.59 | $15.97 | +2.98% |
Click any year to see its month-by-month AGMB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AGMB could reach as high as $15.97, with a base case around $11.67 and support toward $9.85 — roughly 0% from $11.67. Price action looks broadly range-bound.
Expect AGMB to range from $7.92 to $16.84 through 2027. The $11.10 average target implies a -5% move from current prices. That is -5% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The AGMB price prediction for 2028 points to an average of $10.66 (low $7.15, high $17.22) — a potential decline of -9% on today's $11.67. Price action looks broadly range-bound.
In 2029, AGMB is projected to trade between $7.40 and $19.74, averaging $11.64 — a potential decline of 0% from today's $11.67. That is up +9% on the projected 2028 average. A consolidation phase looks the most probable path here.
AgomAb Therapeutics NV's 2030 outlook centres on $11.99, within a $7.25 to $21.17 range. That is up +3% on the projected 2029 average. That marks a +3% change versus current levels. Price action looks broadly range-bound.
By 2031, AGMB could reach as high as $27.61, with a base case around $15.10 and support toward $8.72 — roughly +29% from $11.67. Buyers look set to stay in control over this stretch.
Expect AGMB to range from $9.44 to $32.22 through 2032. The $17.09 average target implies a +46% move from current prices. That is up +13% on the projected 2031 average. Momentum favours further upside here.
The AGMB price prediction for 2033 points to an average of $15.36 (low $8.13, high $29.78) — a potential gain of +32% on today's $11.67. Buyers look set to stay in control over this stretch.
In 2034, AGMB is projected to trade between $8.11 and $31.78, averaging $15.98 — a potential gain of +37% from today's $11.67. That is up +4% on the projected 2033 average. Momentum favours further upside here.
AgomAb Therapeutics NV's 2035 outlook centres on $16.52, within a $8.04 to $33.62 range. That is up +3% on the projected 2034 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AGMB could reach as high as $55.27, with a base case around $24.68 and support toward $11.10 — roughly +111% from $11.67. Momentum favours further upside here.
Expect AGMB to range from $16.74 to $85.55 through 2050. The $37.19 average target implies a +219% move from current prices. That is up +51% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AGMB today (≈ 85.689803 AGMB) could be worth
$3,187.1
+$2,187.1 (+219%) by 2050 · US Dollar
Based on the average projected AGMB price of $37.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AGMBwould be worth at today's price.
$1,000 invested in AGMB on Feb 6, 2026 (≈ 68.259387 AGMB) would be worth
$796.59
-$203.41 (-20.3%) today · 0.80× · US Dollar
Based on a AGMB entry price of $14.65 vs. today's $11.67.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.7 | $1,090.65 | +9.1% |
| 1 month ago | $11.32 | $1,030.92 | +3.1% |
| 3 months ago | $16.01 | $728.92 | -27.1% |
| All time ago | $14.65 | $796.59 | -20.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AGMB forecast.
Our base-case forecast reaches $23.00 around 2040.
Implied market cap at $23.00: $1.13B
The forecast begins with a neutral near term, as 2026 shows an average of $11.50 with ROI 0, followed by 2027 at $10.85 with ROI -5.6, 2028 at $10.45 with ROI -9.1, and 2029 at $11.28 with ROI -1.9, before edging higher in 2030 to an average of $11.51 with ROI 0.1. Beginning in 2031 the outlook turns bullish, with an average of $14.59 and ROI 26.9, followed by 2032 at $16.41 with ROI 42.7, 2033 at $14.66 with ROI 27.5, 2034 at $15.44 with ROI 34.3, and 2035 at $15.87 with ROI 38. The long arc continues with 2040 averaging $23.58 and ROI 105, and 2050 averaging $35.07 and ROI 205.
The sentiment in the later years is BULLISH, but these figures are estimates, not guarantees.
Tap a question to reveal the answer.
The 2030 forecast average is $11.51 with a max of $20.25 and a min of $7.00, and ROI 0.1.
Near-term sentiment is NEUTRAL with a 2026 average of $11.50 and ROI 0. The forecast turns bullish in 2031 with an average of $14.59 and ROI 26.9, continuing through 2050 with higher averages and ROIs. These are estimates, not guarantees.
Yes, the forecast shows years with max prices above $30, including 2032 max $30.81 and 2034 max $30.57, and 2035 max $32.15.
Sentiment is NEUTRAL; RSI14 is 50; SMA50 is $11.41; support at $10.42 and resistance at $12.50. The 30-day price range is $9.04-$14.63.
Current price is $11.50 and market cap is $566.35M; the stock is ranked 2946.
AgomAb Therapeutics NV Community Discussion
0Share your AgomAb Therapeutics NV price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.